Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ARID1A loss |
Therapy | Trastuzumab |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A loss | Her2-receptor positive breast cancer | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896). | 27172896 |
PubMed Id | Reference Title | Details |
---|---|---|
(27172896) | Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. | Full reference... |